NTLA Company Profile and Key Details

Q: Who are the executives of NTLA?

Dr. David Lebwohl M.D.Executive Vice President & Chief Medical OfficerDr. Jennifer A. Doudna Ph.D.Founder & Member of Scientific Advisor BoardMr. Nessan Bermingham Ph.D.Founder & Member of Scientific Advisor BoardDr. John M. Leonard M.D.Pres, Chief Executive Officer & DirectorMr. Glenn G. Goddard CPAExecutive Vice President, Chief Financial Officer & TreasurerDr. Andrew MayFounder and Member of Scientific Advisor BoardDr. Laura Sepp-Lorenzino Ph.D.Executive Vice President & Chief Scientific OfficerMr. James E. Basta Esq., J.D.Executive Vice President, Gen. Counsel & Corporation Sec.Dr. Derrick J. Rossi Ph.D.Founder & Member of Scientific Advisor BoardMr. Derek HicksExecutive Vice President & Chief Bus. Officer

NASDAQ : NTLA

Intellia Therapeutics

$13.42

-0.16-1.18%

At Close 4:00 PM

62.64

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Intellia Therapeutics, Inc. (NTLA) stock declined over -1.18%, trading at $13.42 on NASDAQ, down from the previous close of $13.58. The stock opened at $13.61, fluctuating between $13.41 and $13.93 in the recent session.

Stock Snapshot

13.58

Prev. Close

1.55B

Market Cap

13.41

Day Low

-3.2

P/E Ratio

-4.2

EPS (TTM)

-4.51

Cash Flow per Share

13.61

Open

115.83M

Number of Shares

13.925

Day High

94.95%

Free Float in %

11.61

Book Value

2.23M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 25, 2026	13.60	13.93	13.41	13.42	2.26M
Feb 24, 2026	13.46	13.84	13.12	13.58	2.84M
Feb 23, 2026	12.51	13.19	12.41	13.16	2.32M
Feb 20, 2026	12.79	12.96	12.51	12.64	2.52M
Feb 19, 2026	12.21	13.08	12.10	13.04	2.03M
Feb 18, 2026	12.08	12.70	12.00	12.48	2.51M
Feb 17, 2026	11.83	12.47	11.66	12.22	2.38M
Feb 13, 2026	11.54	12.32	11.54	11.87	2.62M
Feb 12, 2026	11.88	11.95	11.21	11.62	2.94M
Feb 11, 2026	11.89	12.04	11.36	12.00	3.58M
Feb 10, 2026	12.32	12.54	11.75	11.91	2.98M
Feb 09, 2026	12.00	12.50	11.76	12.49	4M
Feb 06, 2026	11.32	12.33	11.32	12.28	4.6M
Feb 05, 2026	11.98	12.20	10.94	11.09	5.81M
Feb 04, 2026	13.03	13.07	11.96	12.36	4.96M
Feb 03, 2026	13.15	13.76	12.51	13.05	3.6M
Feb 02, 2026	13.00	13.41	12.80	13.06	3.18M
Jan 30, 2026	13.46	13.97	12.94	13.15	5.27M
Jan 29, 2026	13.86	14.67	13.67	13.90	4.8M
Jan 28, 2026	14.97	15.00	13.59	13.82	6.04M

Contact Details

Cambridge, MA 02139

United States

https://www.intelliatx.com 857 285 6200

About Company

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Stock Peers

ARGX

-23.33-2.78%

argenx SE$816.95 REGN

12.09+1.57%

Regeneron Pharmaceuticals, Inc.$784.28 UTHR

61.67+13.03%

United Therapeutics Corporation$535.10 VRTX

-4.38-0.90%

Vertex Pharmaceuticals Incorporated$483.05 MDGL

-4.99-1.13%

Madrigal Pharmaceuticals, Inc.$435.01 PRAX

4.84+1.41%

Praxis Precision Medicines, Inc.$347.55 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-5.49-1.65%

Alnylam Pharmaceuticals, Inc.$327.36 KRYS

5.6+2.10%

Krystal Biotech, Inc.$272.50 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Intellia Therapeutics, Inc. (NASDAQ:NTLA) closed at $13.42 USD, losing -$0.16 (-1.18%) from the previous close of $13.58. The stock is currently mid-range between its 52-week high and low $5.90 and $28.25. With a market capitalization of about $1.55 billion, Intellia Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.11). Key stats such as the average daily volume over the past year has been around 4.63 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Intellia Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO John Leonard, the company employs approximately 403 people and listed since May 06, 2016. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics.

Technical Performance

NTLA has shown mixed momentum, gaining 12.25% over the past week and -48.16% over the past quarter, though year-to-date performance is up 42.71%. Short-term trend indicators are mixed aligned (SMA20 6.03%, SMA50 16.14%, SMA200 10.41%). The stock’s 14-day RSI is 57.57 (neutral), while the ATR of 0.89 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -52.5% below its high and over 127.46% above its low. Average 10-day trading volume of 2.41 million shares is below the 3-month average of 4.54 million, indicating normal recent market interest.

Valuation Metrics

Intellia Therapeutics, Inc. trades at a P/E ratio of -3.37, slightly below the S&P 500 average, with a price-to-sales ratio of 27.49 and a price-to-book ratio of 2.01 suggesting the stock is closer to book value. The P/FCF stands at -3.83, also above market averages.

Dividend & Fair Value

Intellia Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$11.54. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Intellia Therapeutics, Inc. generated EPS of -$4.27 over the past year. Five-year average earnings growth is -20.04%. Wall Street analysts project EPS growth of 33.19% annually over the next five years. The latest quarter delivered EPS of -$0.92. The next quarter is forecast at -$0.95. Next year's EPS is expected at -$8.71. Analyst sentiment is bullish. Analyst rating data shows there are 10 Strong Buy ratings, 15 Buy ratings, 9 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $68.00 to $5.00. The high target offers 406.71% upside. The low target suggests -62.74% downside. The mean target is $25.47. This offers 89.79% upside. Intellia Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 06, 2025, missed forecasts by -9.8%. The prior quarter beat by -3.88%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in October 24, 2024.

Shareholding & Insider Activity

Intellia Therapeutics, Inc. has 107.35 million shares outstanding. The public float is 101.92 million shares, elevated short interest at 29.26% of float. This equals 27.73 million shares. The short ratio is 5.6 days. Institutional investors hold 92.91% of the float. Insiders own 4.89%. LEONARD JOHN M holds 1.01 million shares, Cohen Fred E has 207.45 thousand shares and CHASE WILLIAM J has 134.69 thousand shares. Over the past six months, insider transactions show net selling. They sold 91.09 thousand shares across 10 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Intellia Therapeutics generated $36.28M in revenue, or $0.41 per share. Gross margin was 75.26%, operating margin -1420.51%, and net profit margin -1326.51%. Returns are negative, with ROA at -36.99% and ROE at -45.82%.
On valuation metrics, Intellia Therapeutics trades at a P/E of -3.37, P/S of 27.49 and P/B of 2.01. The current ratio is 6.21 and quick ratio is 6.21. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 8.81 days. Debt-to-equity is 0.13, supported by a cash flow-to-debt ratio of -4.19.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Intellia Therapeutics posted revenue of $36.28M, down slightly from $52.12M in the prior quarter. Gross profit was $27.30M (margin 75.26%). Operating income was - $515.29M (margin -1420.5%). Net income was- $481.19M (EPS - $5.42).
The company ended the quarter with $912.22M in cash and short-term investments, a total debt of $115.35M, and net debt of - $111.40M. Total assets were $1.30B, with equity of $1.05B. Financials further reflected weakness, with operating cash flow of - $394.09M, free cash flow of - $408.07M, and capital expenditures of - $13.99M.

Price Forecast & Outlook

Our AI price prediction model suggests that Intellia Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.02%, with price expected at $12.88 by March 11, 2026, within a range of $11.87 to $13.92 3-Month Outlook: Projected fall of -78.99%, reaching $2.82 by May 25, 2026, with a range of $1.85 to $3.34. 1-Year Outlook: Projected gain of 140.83%, with price at $32.32 by February 25, 2027, within a range of $19.31 to $44.14.

Key Takeaways

Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares are up 42.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Intellia Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.37. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $60.27, suggesting 349.11% upside. Our AI forecast model points to short-term weakness (-4.02% over two weeks), a medium-term fall (-78.99% over three months), and a longer-term gain (140.83% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Intellia Therapeutics, Inc. (NTLA) stock price?

Intellia Therapeutics, Inc. (NASDAQ: NTLA) stock price is $13.42 in the last trading session. During the trading session, NTLA stock reached the peak price of $13.93 while $13.41 was the lowest point it dropped to. The percentage change in NTLA stock occurred in the recent session was -1.18% while the dollar amount for the price change in NTLA stock was - $0.16.

NTLA's industry and sector of operation?

The NASDAQ listed NTLA is part of Biotechnology industry that operates in the broader Healthcare sector. Intellia Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NTLA?

Dr. David Lebwohl M.D.
Executive Vice President & Chief Medical Officer
Dr. Jennifer A. Doudna Ph.D.
Founder & Member of Scientific Advisor Board
Mr. Nessan Bermingham Ph.D.
Founder & Member of Scientific Advisor Board
Dr. John M. Leonard M.D.
Pres, Chief Executive Officer & Director
Mr. Glenn G. Goddard CPA
Executive Vice President, Chief Financial Officer & Treasurer
Dr. Andrew May
Founder and Member of Scientific Advisor Board
Dr. Laura Sepp-Lorenzino Ph.D.
Executive Vice President & Chief Scientific Officer
Mr. James E. Basta Esq., J.D.
Executive Vice President, Gen. Counsel & Corporation Sec.
Dr. Derrick J. Rossi Ph.D.
Founder & Member of Scientific Advisor Board
Mr. Derek Hicks
Executive Vice President & Chief Bus. Officer

How NTLA did perform over past 52-week?

NTLA's closing price is 127.46% higher than its 52-week low of $5.90 where as its distance from 52-week high of $28.25 is -52.5%.

How many employees does NTLA have?

Number of NTLA employees currently stands at 403.

Link for NTLA official website?

Official Website of NTLA is: https://www.intelliatx.com

How do I contact NTLA?

NTLA could be contacted at phone 857 285 6200 and can also be accessed through its website. NTLA operates from 40 Erie Street, Cambridge, MA 02139, United States.

How many shares of NTLA are traded daily?

NTLA stock volume for the day was 2.23M shares. The average number of NTLA shares traded daily for last 3 months was 4.63M.

What is the market cap of NTLA currently?

The market value of NTLA currently stands at $1.55B with its latest stock price at $13.42 and 115.83M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	403
Beta	2.11
Sales or Revenue	$36.28M
5Y Sales Change%	-0.422%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

NTLA Company Profile and Key Details

Intellia Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook